Brief: Kiromic Biopharma Says Frank Tirelli Informs The Board That He Is Resigning His Position As Director Of Co
22/11/2022 23:10
Nov 22 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC BIOPHARMA - ON NOV 16, 2022, FRANK TIRELLI
INFORMED THE
BOARD THAT HE WAS RESIGNING HIS POSITION AS A DIRECTOR OF CO,
EFFECTIVE IMMEDIATELY
* KIROMIC BIOPHARMA - AS RESULT OF TIRELLI’S RESIGNATION, CO
WILL
NO LONGER BE IN COMPLIANCE WITH NASDAQ LISTING RULE
5605(C)(2)(A)
Source: (shorturl.at/DHJO5)
Further company coverage: KRBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site